The purpose of this study is to determine whether bindarit is effective to reduce
albuminuria, compared to placebo, in nephropathic patients treated with irbesartan, as a
background therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Aziende Chimiche Riunite Angelini Francesco S.p.A
Collaborator:
Mario Negri Institute for Pharmacological Research